Cargando…

Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy

BACKGROUND: The preferred salvage treatment for children with relapsed/refractory acute myeloid leukemia (R/R‐AML) remains unclear. The combination of cladribine/Ara‐C/granulocyte‐colony stimulating factor and mitoxantrone (CLAG‐M) shown promising results in adult R/R‐AML. We aim to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruan, Min, Liu, Li‐Peng, Zhang, Ao‐Li, Quan Qi, Ben, Liu, Fang, Liu, Tian‐Feng, Liu, Xiao‐Ming, Chen, Xiao‐Juan, Yang, Wen‐Yu, Guo, Ye, Zhang, Li, Zou, Yao, Chen, Yu‐Mei, Zhu, Xiao‐Fan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897947/ https://www.ncbi.nlm.nih.gov/pubmed/33491298 http://dx.doi.org/10.1002/cam4.3681

Ejemplares similares

Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis
por: Cao, Susu, et al.
Publicado: (2023)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia
por: Yang, Lu, et al.
Publicado: (2019)

Cladribine with Granulocyte Colony‐Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study
por: Wang, Hua, et al.
Publicado: (2020)

Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis
por: Zhou, Anqi, et al.
Publicado: (2019)

Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia
por: Liu, Li‐Peng, et al.
Publicado: (2020)

CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study
por: Qian, Jie‐Jing, et al.
Publicado: (2020)

Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long‐term clinical outcomes and health‐related quality of life assessment
por: Yan, Chen‐hua, et al.
Publicado: (2022)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
por: Gill, Harinder, et al.
Publicado: (2020)

Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2018)

CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
por: Farge, Thomas, et al.
Publicado: (2023)

Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia
por: Hu, Xuelian, et al.
Publicado: (2020)

Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway
por: Wang, Hao, et al.
Publicado: (2020)

Correction to: Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2019)

Identification and validation of a prognostic index based on a metabolic-genomic landscape analysis of ovarian cancer
por: Zhang, Qun-feng, et al.
Publicado: (2020)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Cladribine and cytarabine in children refractory high risk multisystem Langerhans cell histiocytosis
por: Wang, Wenqian, et al.
Publicado: (2023)

Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study
por: Huang, Xiaojun, et al.
Publicado: (2018)

PB1848: IN VITRO CHEMOSENSITIVITY ASSAY PREDICTS TREATMENT RESPONSE IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA
por: Cao, Yigeng, et al.
Publicado: (2023)

Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia
por: Lv, Wenxiu, et al.
Publicado: (2023)

Comprehensive analysis of long noncoding RNA and mRNA in five colorectal cancer tissues and five normal tissues
por: Zhou, Zhen-Xu, et al.
Publicado: (2020)

PB1850: MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION COMBINED WITH CLAG REGIMEN IN REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA (NON-M3)
por: Wan, Kai, et al.
Publicado: (2023)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study
por: Xu, Jun, et al.
Publicado: (2018)

Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
por: Chen, Meixia, et al.
Publicado: (2018)

Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia
por: Wang, Liang, et al.
Publicado: (2021)

Deciphering the scalene association among type‐2 diabetes mellitus, prostate cancer, and chronic myeloid leukemia via enrichment analysis of disease‐gene network
por: Liu, Qiong, et al.
Publicado: (2019)

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
por: Jin, Xin, et al.
Publicado: (2022)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
por: Ferraro, Francesca, et al.
Publicado: (2022)

LukS‐PV induces apoptosis in acute myeloid leukemia cells mediated by C5a receptor
por: Zhang, Peng, et al.
Publicado: (2019)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma
por: Ma, Jian, et al.
Publicado: (2011)

Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma
por: Saulnier Sholler, Giselle L, et al.
Publicado: (2015)

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
por: Afolabi, Dayo, et al.
Publicado: (2017)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

A novel upregulated LncRNA‐AC026150.8 promotes chemo‐resistance and predicts poor prognosis in acute myeloid leukemia
por: Zhang, Henan, et al.
Publicado: (2021)

Safety and efficacy of a modified busulfan/cyclophosphamide conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation in acute myeloid leukemia
por: Shi, Yuan-Yuan, et al.
Publicado: (2023)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1pge67km9096i66bulsfdcpk8t